Chat message

Slack / Private Message Drop, p.109 [SLACK_000323] · slack_pm:msg:01118

Date: 2020-07-27 14:48
Type: chat message · slack
recipient: Kristian G. Andersen, Robert F. Garry, Edward C. Holmes
speaker: Andrew Rambaut
Topics: Furin cleavage site and molecular features

Recipients on this medium are inferred from channel membership, not per-message addressing.

But if the acquisition of the furin site is the point at which it becomes epidemic then once again we are back to the common ancestor of the current diversity being in late 2019. We don't have any other nodes to date.

Extracted statements

Rule-extracted, not adjudicated. The grade says what may be done with each one; read the document above before relying on any of them.

Statement	Grade	Attribution	Stance
But if the acquisition of the furin site is the point at which it becomes epidemic then once again we are back to the common ancestor of the current diversity being in late 2019.	own voice, substantive	speaker_own	asserts

Statement

Grade

Attribution

Stance

But if the acquisition of the furin site is the point at which it becomes epidemic then once again we are back to the common ancestor of the current diversity being in late 2019.

own voice, substantive

speaker_own

asserts

In context

A single line often inverts meaning once you see what it answers, so neighbouring messages are always shown.

2020-07-27 14:41 Kristian G. Andersen open

I thought so too, but honing in on specific parts of the genomes that were homologous it seemed like it could bedone - no idea about the details though.
2020-07-27 14:43 Andrew Rambaut open

It also makes no sense that the SARS2 diversity circulating now was part of the pre-circulating scenario. The Wuhanhaplotype may have been around for a month or two prior to Dec 2019 but not much longer given the transmissibilityof the virus. This virus doesn't lurk unobserved.
2020-07-27 14:45 Andrew Rambaut open

Has Trevor found his next thing to go off on Twitter about?
2020-07-27 14:46 Kristian G. Andersen open

"This virus doesn't lurk unobserved" - as is, definitely true - but I _do_ wonder if a pre-furin site virus could. But Iagree with you - I'm not sure such an analysis makes sense given our limited sampling. Assuming SARS2 came outof Yunnan diversity (which seems likely), it would be cool to go do some in-depth sampling from there. And yes, maybe we'll get the big reveal on Twitter :wink:
2020-07-27 14:48 Andrew Rambaut

But if the acquisition of the furin site is the point at which it becomes epidemic then once again we are back to the common ancestor of the current diversity being in late 2019. We don't have any other nodes to date.
2020-07-27 14:50 Kristian G. Andersen open

.... ehm, yes. That is, of course, true... Unless it's been in a freezer since that outbreak in the Mojiang mine...:parrot:
2020-07-27 14:55 Kristian G. Andersen open

And @Robert Garry - I have come around on challenge testing... What I really want to see is early challenge trials invery small (~10-20) groups of people to establish efficacy. If it doesn't work in those, no need to move forward... I'm SUPER uncomfortable with 30,000 people now getting the Moderna vaccine - can you imagine how detrimental thisis going to be for (COVID and otherwise) vaccine research if this vaccine actually isn't safe? Or may even lead toADE?Let's hope it works...
2020-07-27 15:03 Robert F. Garry open

Yeah - that's a good idea - you could get down to the best set of candidates with 10-20 person trials in a few months. Same with the monoclonals, though showing protection in animals before the in-ppl screening would be good.
2020-07-27 15:09 Kristian G. Andersen open

Yup.

Full conversation →